|
|
| Biotechnologies Et Génétique > Etude de marché sectorielle |
| Indian Biotechnology Market Outlook (2006) |
|
|
|
|
€ 1 120,00 |
Editeur
: |
RNCOS |
Langue
: |
Anglais |
Date de publication : |
Février 2007 |
Taille du document : |
90 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (5) |
|
|
|
| 52 pages | Mars 2001 | Anglais
|
|
|
| Main
focus: |
biotechnology,bioinformatics,bio informatics,...,...
|
| Research
focus: |
market size and estimates,market segmentation, |
| Geographic
focus: |
canada,united kingdom,usa,france |
| |
|
|
|
|
| 271 pages | Juillet 2006 | Anglais
|
|
|
| Main
focus: |
biotechnology,biotech,biotech crops,bioinformatic,...,...
|
| Research
focus: |
competition analysis,market size and estimates, |
| Geographic
focus: |
france,united kingdom,hungary,czech republic,... |
| |
|
|
|
|
| 90 pages | Janvier 1998 | Anglais
|
|
|
| Main
focus: |
biotechnology,biotech,genetics,drug discovery,...
|
| Research
focus: |
competition analysis,market outlook, |
| Geographic
focus: |
usa,india,uruguay,chile,colombia,venezuela,... |
| |
|
|
|
|
| 44 pages | Juin 2005 | Anglais
|
|
|
| Main
focus: |
pharmaceutical,pharmaceutical industry,...,...
|
| Research
focus: |
demand analysis,market size and estimates, |
| Geographic
focus: |
france,germany,united kingdom,japan,spain,... |
| |
|
|
|
|
| 44 pages | Janvier 2001 | Anglais
|
|
|
| Main
focus: |
biotechnology,biotech,biotechnology patents,...,...
|
| Research
focus: |
market size and estimates,market definition, |
| Geographic
focus: |
usa,switzerland,united kingdom,germany,france |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Target and Lead Validation 160 pages | Décembre 2000 |
The advent of brute force approaches to lead generation has highlighted a key bottleneck in drug development. The issue is not how many new compounds can one make per day, but rather how many c |
1 400,00 €
|
| |
| |
Biochips IRCD pages | Juillet 2001 |
The notion of a cheap and reliable computer chip look-alike that performs thousands of biological reactions is a very attractive one, because it miniaturizes, automates and accelerates otherwise cumbe |
1 200,00 €
|
| |
| |
Biochips 150 pages | Décembre 2000 |
The notion of a cheap and reliable computer chip look-alike that performs thousands of biological reactions is a very attractive one, because it miniaturizes, automates and accelerates otherwise cumbe |
1 400,00 €
|
| |
| |
Nanotechnology: Emerging Trends
30 pages | Avril 2003 |
Recently, nanotechnology has become extremely popular and is used to describe many types of research where the characteristic dimensions are less than about 1,000 nanometers. Nanotechnology also pr |
550,00 €
|
| |
| |
Chinese Markets for Biotechnology 153 pages | Janvier 2002 |
China's demand for biotechnology has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic t |
2 835,00 €
|
| |
| |
Revolutionise Drug Discovery through Genomics & Proteomics Study 10 pages | Novembre 2002 |
Genomics and Proteomics are complementary technologies of biological research. The potential of these technologies for biomedical revolution will be realized by integrating them into the drug disc |
200,00 €
|
| |
| |
The Genomics Outlook To 2005: Transforming pharmaceutical and diagnostic markets 150 pages | Janvier 2002 |
Genomics is quietly transforming the pharmaceutical industry. Companies are moving from medicinal chemistry based drug discovery and development, to using information provided by genomics. V |
953,48 €
|
| |
| |
Biotech Industry Potential: Emerging Markets & Trends 15 pages | Novembre 2002 |
The global biotech industry is comprised of 4,284 companies in 25 nations. The 622 public companies generated revenues of $35 billion, spent $16 billion in R&D and employed more than 188,000 people |
250,00 €
|
| |
| |
Lead Validation Platforms IRCD pages | Juillet 2001 |
The advent of brute force approaches to lead generation has highlighted a key bottleneck in drug development. The issue is not how many new compounds can one make per day, but rather how many c |
1 200,00 €
|
| |
| |
03-071: Service & Support for Life Science Products 160 pages | Janvier 2004 |
This report examines the expectations of scientific customers as they relate to service and technical support from their suppliers |
1 280,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Indian Biotechnology Market Outlook (2006) |
|
|
The report “Indian Biotechnology Market Outlook (2006)” provides an updated and detailed overview of the Indian Biotechnology industry. It examines the emerging trends and provides exclusive forecasts and segment-wise snapshots of biotechnology industry in India. Report also highlights the information regarding Biotech parks in India and region-wise Biocluster.
Key Findings
§ Growing at the rate of 28.09% from the year 2005, Indian Biotechnology industry is likely to touch the mark of US$ 5 Billion by the end of 2010. § India will emerge as a key destination for clinical trials & stem cell research. § Biotechnology will play an important role in Agriculture sector by developing large number of genetically modified crops. § BioPharma industry, comprising of vaccines, therapeutics and other products, will emerge as major segment of Indian Biotech industry.
Key Issues and Facts Analyzed
The research report also addresses the issues and facts that are critical to your success:
§ What are the market trends in the Indian Biotechnology industry? § Where the market will be after 5 years? § What opportunities exist in Indian Biotechnology industry? § What are the driving factors for the Indian Biotechnology industry? § What are the challenges faced by Biotechnology industry? § Who are the main players in the Indian Biotechnology industry?
Key Players Analyzed
This section provides the overview and key financial information of prominent players in the Indian Biotechnology Industry, like Biocon, Serum Institute of India, Nicholas Piramal India Limited (NPIL), Wockhardt Limited, GlaxoSmithKline, Bharat Serums and Vaccines (BSV), Zydus Cadila, Indian Immunologicals Limited (IIL), Krebs Biochemical’s & Industries Limited (KBIL), Novo Nordisk, Mahyco Monsanto, Bharat Biotech, Abbott, Ranbaxy, Novozymes etc.
Research Methodology Used
Information Sources Information has been sourced from books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.
Analysis Methods The analysis methods includes the following: Ratio Analysis, Historical Trend Analysis, Linear Regression Analysis using software tools, Judgmental Forecasting and Cause and Effect Analysis.
|
|
1. Analyst View 2. Research Overview 3. Biotechnology Industry Overview 3.1 Biotechnology Industry - Worldwide 3.2 Biotechnology Industry - Asia-Pacific 3.3 Biotechnology Industry - India 4. Indian Biotechnology Industry Performance 4.1 Market Size 4.2 Biotech Domestic and Exports Market 4.3 Biotech Market Segmentation 4.3.1 Biopharmaceuticals 4.3.2 BioServices (Contract Research) 4.3.3 Agri Biotech 4.3.4 Industrial Biotech 4.3.5 Bioinformatics 4.4 Biotech Parks 4.4.1 Shapoorji Pallonji Biotech Park 4.4.2 ICICI Knowledge Park 4.4.3 International Biotech Park 4.4.4 Lucknow Biotech Park 4.4.5 Ticel Bio Park 4.4.6 Upcoming Parks 4.5 Investments in Indian Biotechnology Sector 4.6 Employment Opportunities in Biotech Sector 4.7 National Biotechnology Development Strategy 5. Indian Bio-Clusters 5.1 Southern Region 5.1.1 Andhra Pradesh - The Hyderabad Bio-Cluster 5.1.2 Karnataka - The Bangalore Bio-Cluster 5.1.3 Tamil Nadu - The Chennai Bio-Cluster 5.1.4 Kerala 5.2 Western Region 5.2.1 Maharashtra - The Pune Bio-Cluster 5.2.2 Gujarat 5.3 Northern Region 5.3.1 Uttar Pradesh - Lucknow 5.3.2 Punjab 6. Industry Analysis 6.1 Key Driving Forces 6.1.1 Human Resources 6.1.2 Strong Bio-processing Skills 6.1.3 Bio-diversity 6.1.4 Regulatory Framework 6.2 Opportunity 6.2.1 Outsourcing of Preliminary Research 6.2.2 Off-patent Drug 6.2.3 Clinical Trial Opportunity 6.2.4 Bioinformatics 6.2.5 Stem Cell Research 6.2.6 Agricultural Biotechnology 6.2.7 Biofuel 6.2.8 Biofertilizers/BioPesticides 6.3 Challenges 6.3.1 Lack of IPR (Intellectual Property Rights) Regime 6.3.2 Time to Market 6.3.3 Seed Funding 6.3.4 Synergy between Stakeholders 6.3.5 High Innovative Drug Cost 6.3.6 Regulatory Issues 6.4 Future Outlook, 2010 7. Key Players and Company Profiles 7.1 Biotech Suppliers 7.2 Biotech Companies 7.3 Company Profiles 7.3.1 Biocon 7.3.2 Serum Institute of India 7.3.3 Panacea Biotech 7.3.4 Nicholas Piramal India Limited (NPIL) 7.3.5 Wockhardt Limited 7.3.6 GlaxoSmithKline 7.3.7 Bharat Serums and Vaccines (BSV) 7.3.8 Krebs Biochemical’s & Industries Limited (KBIL) 7.3.9 Zydus Cadila 7.3.10 Indian Immunologicals Limited (IIL) 7.3.11 Shantha Biotechnics 7.3.12 Biological E 7.3.13 Chiron Behring Vaccines 7.3.14 Eli Lilly 7.3.15 Novo Nordisk 7.3.16 Mahyco Monsanto 7.3.17 Bharat Biotech 7.3.18 Abbott 7.3.19 Ranbaxy 7.3.20 Novozymes 8. Annexure I: Government Initiatives and Regulations 8.1 Fiscal Incentives Provided to the Biotech Sector 8.1.1 Tax 8.1.2 Regulatory 8.1.3 Investment 8.2 Important Changes to the Patents Act in the Third Amendment Bill 8.2.1 Substantive Changes 8.2.2 Procedural Changes 8.3 Plant Varieties and Farmers’ Rights Protection Act, 2001 8.4 Other Regulations impacting the Biotech Sector 8.4.1 Licensing 8.4.2 Clinical Trials 8.4.3 Seeds Act and Policy 8.4.4 Environmental Clearances 8.4.5 Biological Diversity Act
List of Figures:
Figure 3-1: Worldwide - Biotechnology Market (in Billion US$), 2001-2006E Figure 3-2: Worldwide - Biotechnology Market Share by Region (%), 2005 Figure 3-3: Worldwide - Biotechnology Market Share by Segment (%), 2005 Figure 3-4: Worldwide - Forecast for Biotechnology Market (in Billion US$), 2007-2010 Figure 3-5: Asia-Pacific - Biotechnology Market (in Billion US$), 2001-2005 Figure 3-6: Asia-Pacific - Biotechnology Market Share by Region (%), 2005 Figure 3-7: Asia-Pacific - Biotechnology Market Share by Segment (%), 2005 Figure 3-8: Asia-Pacific - Forecast for Biotechnology Market (in Billion US$), 2006-2010 Figure 3-9: India - Budget Allocations of Major Biotechnology Funding Agencies (in Million US$), 1990-91, 2000-01, 2002-03 to 2004-05 Figure 4-1: India - Biotechnology Industry Revenue Growth (in Million US$), 2002-03 to 2005-06 Figure 4-2: India - Market Size of Biotech Industry (in Million US$), 2003-04 to 2005-06 Figure 4-3: India - Biotechnology Market Share by Segment (%), 2004-05 & 2005-06 Figure 4-4: India - Domestic Market and Exports Market of Biotech Industry (%), 2005-06 Figure 4-5: India - Biotech Exports Market Segment (%), 2004-05 & 2005-06 Figure 4-6: India - Biotech Domestic Market Segment (%), 2004-05 & 2005-06 Figure 4-7: India - Biotech Domestic Market (in Million US$), 2005-06 Figure 4-8: India - Bioipharma Segment (%), 2004-05 & 2005-06 Figure 4-9: India - Revenues from BioPharma (in Million US$), 2004-05 & 2005-06 Figure 4-10: India - Recombinant Therapeutics Products Market (in Million US$), 2005-06 Figure 4-11: India - Market Share of BioServices Companies (in Rs Crore), 2005-06 Figure 4-12: India - Agri Biotech Components’ Market (%), 2004-05 Figure 4-13: India - BT Cotton Seeds Revenues (in Rs Crore), 2003-04 & 2004-05 Figure 4-14: India - Industrial Biotech Market (in Million US$), 2003-04 to 2005-06 Figure 4-15: India - Bio-Industrial Companies Revenue (in Million US$), 2003-04 & 2004-05 Figure 4-16: India - Industrial Biotech Share by Sector (%), 2005-06 Figure 4-17: India - Growth in Revenue of Major BioIndustrial Firms (%), 2003 to 2005 Figure 4-18: India - Bioinformatics Market (in Million US$), 2003-04 to 2006-07E Figure 4-19: India - Investments in Biotech Industry (in Million US$), 2000-01 to 2005-06 Figure 4-20: India - Total Manpower in Biotech Sector (in Numbers), 2002-03 to 2004-05 Figure 4-21: India - Human Resource Allocation in Biotech Sector (%), 2006 Figure 5-1: India - Revenue of Biotech Industry by Region (%), 2005-06 Figure 6-1: India - Forecast for Biotechnology Industry (in Billion US$), 2006-2010 Figure 7-1: India - Revenue of Top 20 Bio-Suppliers by Region (%), 2004-05
List of Tables:
Table 4-1: India - Segment-wise Exports of Biotech Industry (in Million US$), 2005-06 Table 4-2: India - BT Cotton Sales (in Packets), 2003-2005 Table 4-3: India - Permitted BT Cotton Seeds Table 7-1: India - Revenue of Top 20 Bio-Suppliers (in Rs Crore), 2003-04 & 2004-05 Table 7-2: India - Top 20 Biotech Companies by Revenue (in Rs. Crore), 2005-06 Table 7-3: Top 20 Biotech Companies of Indian Origin by Revenue (in Rs. Crore), 2004-05 & 2005-06 Table 7-4: Biocon - Key Financials (in Million Rs), 2004-05 & 2005-06 Table 7-5: Panacea Biotech - Key Financials (in Million Rs), 2004-05 & 2005-06 Table 7-6: Nicholas Piramal India Limited - Key Financials (in Million Rs), 2004 &2005 Table 7-7: Wockhardt Limited - Key Financials (in Billion Rs), 2004 & 2005 Table 7-8: GlaxoSmithKline - Key Financials (in Million US$), 2004 & 2005 Table 7-9: Krebs Biochemical’s & Industries Limited - Key Financial (in Million US$), 2004-05 & 2005-06 Table 7-10: Abbott - Key Financial (in Million Rs), May 2006 Table 7-11: Ranbaxy - Key Financials (in Million Rs), 2005
|
|
|
PPLSEN
|
|
|
|
|